

# COVIDTrach: a prospective cohort study of mechanically ventilated patients with COVID-19 undergoing tracheostomy in the UK

COVIDTrach collaborative

**To cite:** . COVIDTrach: a prospective cohort study of mechanically ventilated patients with COVID-19 undergoing tracheostomy in the UK. *BMJ Surg Interv Health Technologies* 2021;3:e000077. doi:10.1136/bmjst-2020-000077

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjst-2020-000077>).

Received 19 December 2020  
Accepted 09 June 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Division of Surgery & Interventional Science, University College London, London, UK

**Correspondence to**  
Nick Ji Hamilton;  
[nick.hamilton@ucl.ac.uk](mailto:nick.hamilton@ucl.ac.uk)

## ABSTRACT

**Objectives** COVIDTrach is a UK multicentre prospective cohort study project that aims to evaluate the outcomes of tracheostomy in patients with COVID-19 receiving mechanical ventilation and record the incidence of SARS-CoV-2 infection among healthcare workers involved in the procedure.

**Design** Data on patient demographic, clinical history and outcomes were entered prospectively and updated over time via an online database (REDCap). Clinical variables were compared with outcomes, with logistic regression used to develop a model for mortality. Participants recorded whether any operators tested positive for SARS-CoV-2 within 2 weeks of the procedure.

**Setting** UK National Health Service departments involved in treating patients with COVID-19 receiving mechanical ventilation.

**Participants** The cohort comprised 1605 tracheostomy cases from 126 UK hospitals collected between 6 April and 26 August 2020.

**Main outcome measures** Mortality following tracheostomy, successful wean from mechanical ventilation and length of time from tracheostomy to wean, discharge from hospital, complications from tracheostomy, reported SARS-CoV-2 infection among operators.

**Results** The median time from intubation to tracheostomy was 15 days (IQR 11, 21). 285 (18%) patients died following the procedure. 1229 (93%) of the survivors had been successfully weaned from mechanical ventilation at censoring and 1049 (81%) had been discharged from hospital. Age, inspired oxygen concentration, positive end-expiratory pressure setting, fever, number of days of ventilation before tracheostomy, C reactive protein and the use of anticoagulation and inotropic support independently predicted mortality. Six reports were received of operators testing positive for SARS-CoV-2 within 2 weeks of the procedure.

**Conclusions** Tracheostomy appears to be safe in mechanically ventilated patients with COVID-19 and to operators performing the procedure and we identified clinical parameters that are predictive of mortality.

**Trial registration number** The study is registered with ClinicalTrials.gov (NCT04572438).

## INTRODUCTION

Data indicate that 5%–12% of patients with SARS-CoV-2 infection develop a severe illness requiring critical care, of whom 72%–81%

## Key messages

### What is already known about this subject?

- In the prepandemic setting, tracheostomy is deployed routinely in intensive care patients who required prolonged mechanical ventilation.
- A number of single-centre studies have reported successful outcomes in terms of weaning from ventilation following tracheostomy in patients with COVID-19.
- High rates of infection with SARS-CoV-2 among operators performing the tracheostomy have not been reported in the small number of series that examine this question.

### What are the new findings?

- We provide outcome data on a national cohort of patients with COVID-19 undergoing tracheostomy and show mortality is not higher than expected.
- Age, days of mechanical ventilation preprocedure, inspired oxygen concentration and positive end-expiratory pressure setting at the time of tracheostomy and upward trending C reactive protein are independently associated with mortality.
- Out of the 1605 tracheostomy cases reviewed, only six cases of SARS-CoV-2 infection among operators were reported.

### How might these results affect future research or surgical practice?

- The data support the use of tracheostomy among patients with COVID-19 requiring prolonged mechanical ventilation.
- The clinical parameters highlighted in this report should be considered in the clinical decision-making of when to proceed with tracheostomy in ventilated patients with COVID-19.

require invasive mechanical ventilation.<sup>1–5</sup> Standard UK intensive care practice is to consider tracheostomy after 7–10 days of invasive mechanical ventilation to aid weaning, facilitate comfort and minimise complications relating to the prolonged presence of an oral endotracheal tube.<sup>6–9</sup> However, the role of tracheostomy in mechanically



ventilated patients with COVID-19 remains controversial. Guidance at the start of the pandemic, based largely on expert opinion, recommended avoiding or delaying tracheostomy until 14–21 days after intubation,<sup>10–12</sup> and to only proceed once the patient was COVID-19 reverse transcription (RT)-PCR test negative.<sup>13–15</sup> These measures aimed to prevent nosocomial infection among healthcare professionals and to avoid futile procedures in ventilated patients with COVID-19 who were predicted not to survive or benefit from the procedure.<sup>16–17</sup> These recommendations have since been challenged as the risk of transmission is now known to decline shortly after symptom onset and the outcome of COVID-19 testing is believed not to correlate with risk of infectivity later in the disease process.<sup>18–19</sup> COVIDTrach is a UK multidisciplinary collaborative project that was established to provide an evidence base for the role of tracheostomy in mechanically ventilated patients with COVID-19 in intensive care units (ICUs) and to assess the occurrence of SARS-CoV-2 infection among operators. An interim report documenting the first 548 patients during the first 2 months of the pandemic reported a hospital mortality of 12%, weaning success in 52% and no instances of SARS-CoV-2 infection among operators at the time of writing.<sup>20</sup> This article presents a larger cohort of 1605 patients and links clinical parameters to patient outcomes using regression analysis and predictive modelling.

## METHODS

### Study design

An invitation for clinicians to participate in the COVIDTrach project was disseminated via the UK Federation of Surgical Specialty Associations, its various member organisations and the Intensive Care Society to reach all UK departments involved in tracheostomy in patients with COVID-19. Inclusion into the study was also advertised on societal websites and social media. Overall, 137 hospital sites agreed to participate across all four nations of the UK.

### Patient population

Each participating hospital included all consecutive adult patients over 18 years of age with COVID-19 who underwent elective tracheostomy while receiving invasive mechanical ventilation. Infection was identified by a positive viral RNA test on quantitative RT-PCR testing or when strongly suspected on history, laboratory and radiological findings in the absence of viral RNA test availability or a positive result. Patients under the age of 18 years and those undergoing emergency tracheostomy were excluded.

### Clinical indicators and outcome measures

Demographic data, clinical characteristics, SARS-CoV-2 status, ventilatory requirements before tracheostomy, details of the tracheostomy and the use of personal protective equipment (PPE) were all recorded (data

dictionary in online supplemental appendix). Clinical outcomes included complications, mortality, time from tracheostomy to weaning from mechanical ventilation, success, and time to tracheostomy decannulation, and time from tracheostomy to hospital discharge. Successful weaning was defined as being free from pressure support for greater than 24 hours. Participants were also asked to report whether any of the operators performing the procedure tested positive for SARS-CoV-2 within 2 weeks of the procedure.

### Procedures

Data were collected using an online survey tool (REDCap) with return codes issued to allow participants to update clinical outcomes prospectively. All participants were asked to update the clinical outcomes of their cases by 1 July 2020 and confirm the data were complete. Hospital sites with missing data or data were followed up over the course of July and early August. Hospitals with datasets not updated by 15 August 2020 were removed from the study (n=11).

### Data governance

All data collected were anonymised and non-identifiable and did not alter the patient's clinical care. Participant consent was not sought as per the UK Control Of Patient Information (COPI) notice (Department of Health and Social Care, 2020).

### Statistical analysis

Variables are presented using either mean (SD), median (IQR) or number (percentage), as appropriate. Groups of variables were compared using either t-tests or  $\chi^2$  tests, as appropriate. For regression analysis, all numerical variables, except age and body mass index, were log transformed to remove positive skewness. Logistic regression was used to develop a model for mortality, after imputing missing values using multiple imputation via chained equations.<sup>21</sup> In detail, the imputation model included all potential predictor variables as well as the outcome; 10 imputed datasets were produced. Backwards elimination at the 15.7% significance level was used to remove unimportant variables from the model. This model was internally validated using tenfold cross-validation. Model performance (calibration and discrimination) was assessed using the calibration slope and calibration in the large, and receiver operating characteristic (ROC) curves. Multiple regression was used to develop a model for (log) time to wean success, since we only had information on those for whom wean was successful and hence there was no censoring. Backward elimination was again applied at the 15.7% significance level.

## RESULTS

### Participants

Between 6 April and 26 August 2020, data were received on 1605 tracheostomies from 126 UK hospitals led by a

combination of ENT, maxillofacial and intensive care specialists. The number of tracheostomy cases entered by each hospital ranged from 1 to 106 (mean 12, SD 15.2). Across all cases, over 90% of all data points were completed in all but three variables where completeness was 85% or greater (online supplemental table 1). The average patient age was 58±11 years, with a 70:30 male-to-female ratio. More detailed patient demographics and medical history are presented in [table 1](#) and COVID-19 test status in [table 2](#).

### Tracheostomy procedure

The median time from intubation to tracheostomy was 15 days (IQR 11, 21) ([figure 1A](#)). Overall, 73 (4.5%) patients had tracheostomy within 4 days of intubation and 227 (14%) after 25 days. The mean C reactive protein (CRP) on the day of tracheostomy was 119 (SD, 88) mg/L.

‘Anticipated prolonged wean’ was the most cited indication for tracheostomy in 1473 (92%). An open method of tracheostomy was used in 797 (50%) procedures, percutaneous method in 771 (48%) and a hybrid method using a combination of open and percutaneous techniques in 31 (2%) ([figure 1B](#)). Bronchoscopy was used as an aid in 574 (78%) percutaneous techniques. Patient factors likely to make the tracheostomy more challenging were reported in 327 (41%) open and 109 (14%) percutaneous tracheostomies. Of these, neck obesity was the most frequently reported, occurring in 242 (30%) of all open tracheostomies.

Operators used either a mask with FFP3 level filtration or powered air-purifying respirator (PAPR) in 1563 (99%) of cases ([figure 2C](#)). Other PPE included double gloves in 1460 (91%), a surgical gown in 1511 (94%) and a face visor was used in 1261 (96%) of cases in addition to an FFP3 mask.

### Complications

Intraoperative complications were reported in 147 (9%) procedures with oxygen desaturation below 80% being the most common (n=67), followed by intraoperative bleeding (n=29). Postoperative complications occurred in 356 (22%) cases; bleeding was reported in 119 (7%) patients, more frequently following open procedures (p<0.001). A leak around the tracheostomy cuff necessitating a change in tube was reported in 75 (5%) cases, 48 of these were open tracheostomies.

### Outcomes

One patient died during the tracheostomy procedure, two hundred and seventy-six (17%) patients died before weaning from mechanical ventilation and a further nine (1%) patients died between successful weaning and hospital discharge ([table 3](#)). Overall, 249 (89%) deaths were COVID-19 related and nine patients died of tracheostomy-related complications. The median time from tracheostomy to death was 9 days (IQR 5, 14).

Characteristics of survivors and non-survivors are shown in online supplemental table 2. A multivariable logistic

**Table 1** Patient demographics and medical history of 1605 mechanically ventilated patients with COVID-19 who underwent tracheostomy

Demographics	Patients with COVID-19 undergoing tracheostomy
<b>Age (years) (N=1605)</b>	
Mean (SD)	58 (11)
<b>Sex n (%) (N=1605)</b>	
Male	1122 (70)
Female	482 (30)
<b>Body mass index n (%)</b>	
<18.5	13 (<1)
18.5–24.9	355 (25)
25–29.9	478 (33)
30–39.9	468 (33)
≥40	122 (8)
(N=1437/1605)	
<b>Medical history</b>	
Time from admission to hospital to intubation, median (IQR)(N=1518/1606)	2 (0, 4)
Use of NIV between admission to hospital and intubation n (%) (N=1525/1605)	651 (43)
Time from intubation to tracheostomy in days, median (IQR)(N=1565/1605)	15 (11, 21)
<b>Relevant comorbidities n (%)</b>	
None	391 (24)
1	563 (35)
2	412 (26)
3	120 (7)
>3	36 (2)
(n=1521/1605)	
<b>Temperature at tracheostomy &gt;37.5°C, n (%)</b>	
Day of tracheostomy	377 (23)
1–2 days before	403 (25)
3–4 days before	250 (16)
5 days before	451 (28)
(N=1481/1605)	
<b>CRP at the time of tracheostomy</b>	
CRP downtrending	1070 (68%)
Mean CRP (SD)	119 (88)
Median CRP (IQR)	100 (50, 165)
(N=1583/1605)	
<b>Inotropic support at the time of tracheostomy, n (%)</b>	
	606 (39)
(N=1565/1605)	
<b>Ventilatory requirements on the day of tracheostomy, median (IQR)</b>	
FiO <sub>2</sub> (%) (N=1549/1605)	40 (30, 45)
PaO <sub>2</sub> (kPa) (N=1549/1605)	9.8 (9, 11)
PEEP (cmH <sub>2</sub> O) (N=1533/1605)	8 (6, 10)
PaO <sub>2</sub> /FiO <sub>2</sub> ratio	195 (153, 248)

N represents the number of survey responses over the total number of possible responses as an indicator of data completeness (see also online supplemental table 1). CRP, C reactive protein; FiO<sub>2</sub>, inspired oxygen concentration; NIV, non-invasive ventilation; PaO<sub>2</sub>, arterial oxygen tension.

**Table 2** The outcome of COVID-19 PCR testing in 1605 mechanically ventilated patients with COVID-19 undergoing tracheostomy

**COVID-19 PCR test in patients undergoing tracheostomy**


Test positive during admission to hospital n (%)	
Positive	1473 (92)
Negative	126 (8)
Total number of tests during admission to hospital	
Median (IQR)	1 (1,2)
Outcome of last test before tracheostomy n (%)	
Positive	1213 (83)
Negative	242 (17)
Outcome of second to last test before tracheostomy n (%)	
Positive	678 (75)
Negative	228 (25)
Number of cases with two negative tests before tracheostomy n (%)	115 (7)
Number of days from last test to tracheostomy	
Median (IQR)	12 (6,18)

regression model was fitted for mortality and backward elimination applied. Age, days of mechanical ventilation preprocedure, inspired oxygen concentration and positive end-expiratory pressure (PEEP) setting at the time of tracheostomy, use of inotropic support (all  $p < 0.001$ ), upward trending CRP ( $p = 0.003$ ), fever ( $p = 0.003$ ) and use of anticoagulation ( $p = 0.002$ ) are independently associated with mortality (figure 2A).

Internal validation using tenfold cross-validation produced an average ROC area of 0.75 (range: 0.64–0.87), suggesting good discrimination (figure 2B). The Hosmer-Lemeshow test results in each cross-validation fold suggest no problems with calibration. A comparison of observed and predicted outcomes suggests good agreement (figure 2C).

Of the survivors, 1229 (93%) had been successfully weaned at the time of analysis with 1154 (88%) having undergone successful tube decannulation and 1049 (81%) discharged from hospital (table 3). Median time from tracheostomy to discharge from hospital in survivors was 29 days (IQR 21, 42).

Characteristics of surviving patients according to length of time to successful wean from ventilation are shown in online supplemental table 3. A multiple regression model for time to wean success was fitted and backward elimination applied. These results suggest that advanced age, male sex, higher PEEP setting, higher inspired oxygen requirement, use of anticoagulation (all  $p < 0.001$ ) and non-invasive ventilation before tracheostomy ( $p = 0.003$ ) were all independently associated with prolonged periods of ventilation following tracheostomy among those for whom wean was successful (figure 2D). An association was found between insertion technique and time to successful wean, although the difference was small (median 12 days for percutaneous vs 11 days



**Figure 1** (A) Length of time from intubation to tracheostomy (days). (B) Number of tracheostomies divided by method and specialist performing the procedure. (C) Type of respirator used during the tracheostomy, x axis=total number of cases using that type of respirator. PAPR; powered air-purifying respirator.


for open method). No association was found between time from intubation to tracheostomy and time from tracheostomy to successful ventilatory wean ( $p = 0.92$ ).

### SARS-CoV-2 infection in operators

The question ‘Did any of the operators test positive for COVID-19 within 2 weeks of the procedure?’ was answered in 97% (1558/1605) of cases. Six instances were reported across four hospitals, four after percutaneous tracheostomy and two after open tracheostomy. Five of the cases were performed in intensive care and four within a negative pressure environment. PPE used in these cases included an FFP3 mask in four cases, a fluid-resistant hood with face visor in one, and a PAPR device in one.

### DISCUSSION

This study involved 126 UK hospitals reporting on 1605 individual tracheostomies between March and August 2020.



**Figure 2** (A) ORs from multivariable logistic regression model for mortality (n=1566). Eight predictive clinical variables were identified. Days of ventilation, FiO<sub>2</sub> and PEEP setting are presented using categories to aid interpretation. (B) ROC curve for multivariable prediction model. Internal validation using tenfold cross-validation produced an average ROC area of 0.75 (range: 0.64–0.87). (C) Observed and predicted risk for 10 quantile groups. The groups (1–10) were obtained by splitting patients by their predicted risk, that is, group 1 comprise the 10% of patients with the lowest predicted risk. (D). Regression coefficients from multiple regression model for time to wean success (n=1031). CRP, C reactive protein; FiO<sub>2</sub>, inspired oxygen concentration; NIV, non-invasive ventilation.

During this same period, 7792 patients were recorded by the UK's Intensive Care National Audit & Research Centre (ICNARC) as receiving advanced respiratory support in England, Wales and Northern Ireland.<sup>22</sup> Gender ratio, mean age and body mass index grouping are all comparable between the COVIDTrach database and the ICNARC database indicating our cohort is representative, and the results are likely generalisable to the UK.

At the time of censoring, all-cause mortality following tracheostomy in our cohort was 18%. This number is

likely to rise as 91 patients were still mechanically ventilated and a further 171 had been weaned but were still in hospital. Prospective multicentre studies of general (non-COVID-19) intensive care populations patients report mortality rates of approximately 30% in the first 30 days following tracheostomy.<sup>23 24</sup> Direct comparisons to this cohort of patients with COVID-19 cannot, however, be drawn as demographics, comorbidities and underlying pathologies will differ considerably and timing of tracheostomy is usually performed earlier than the median 15

**Table 3** Outcomes of mechanically ventilated patients with COVID-19 undergoing tracheostomy

Outcomes following tracheostomy in patients with COVID-19	
All cause mortality following tracheostomy in patients with COVID-19, n (%)	
Died during tracheostomy	1 (<1)
Died before successful wean from mechanical ventilation	276 (17)
Died between wean from ventilation and discharge from hospital	9 (1)
Cause of death following tracheostomy, n (%)	
COVID-19 related	249 (89)
Tracheostomy related	9 (3)
Other	22 (8)
Weaning from mechanical ventilation in survivors, n (%)	
Successfully weaned from mechanical ventilation	1229 (93)
Still ventilated at the time of analysis	91 (7)
Time (days) from tracheostomy to successful wean, median (IQR)	11 (7, 18)
Total length (days) of critical care in survivors, median (IQR)	33 (25, 44)
Total length (days) of critical care in non-survivors, median (IQR) (N=264)	23 (16, 32)
Successful tracheostomy decannulation at analysis, n (%)	
Discharge from hospital, n (%)	1049 (81)
Time (days) from tracheostomy to discharge from hospital in survivors, median (IQR)	29 (21, 42)

days following intubation reported in this study of patients with COVID-19. National data, reported in the ICNARC registry, indicate that the ICU mortality rate in mechanically ventilated patients with COVID-19 was 47.8%; however, median duration of critical care stay in non-survivors was 10 days (IQR 6, 17).<sup>22</sup> Given median time to tracheostomy in our cohort was 15 days, patients with COVID-19 undergoing tracheostomy constitute a preselected population who have survived the acute phase and, in general, would have cardiorespiratory stability and are no longer requiring high-level ventilatory support and high-inspired oxygen concentrations. Nonetheless, our data show that tracheostomy in the setting of SARS-CoV-2 infection is not a futile intervention as previously claimed by expert opinion at the start of the pandemic.<sup>16 17</sup>

Whether the timing of tracheostomy does influence patient with COVID-19 outcomes is unclear. Early tracheostomy may benefit certain patient groups,<sup>25 26</sup> but meta-analyses have failed to show benefit in a general population of critically ill adults.<sup>27 28</sup> In our cohort, early tracheostomy was independently associated with higher mortality. Moreover, no association was demonstrated between early tracheostomy and shortened time to successful weaning

from ventilation. Cause and effect cannot be directly inferred from these data and only prospective randomised studies could address this important question.

We found no association between method of tracheostomy and likelihood of successful wean from ventilation, mortality, or discharge from hospital. As in non-COVID-19 series, bleeding was more frequent using the open method, although the overall rate of reported bleeding was low. The percutaneous method has several advantages centred around the ability to perform the procedure at the bedside. In contrast, the open method enables safe procedure in those with difficult neck anatomy and enables the surgical workforce to relieve the task from intensive care staff during periods when a critical care department is working at full capacity. The decision over which method to employ should be locally led and depends on expertise available and close interdisciplinary working.

The low rates of reported SARS-COV-2 infection among operators who likely continued to work in other high-risk areas and performed other aerosol generating procedures are encouraging. While asymptomatic cases may have been missed and recall bias may have occurred, the low rates of infection suggest that, with appropriate PPE, the procedure does not pose a high risk of infection with SARS-COV-2 to operators. Our findings are consistent with other series.<sup>29 30</sup>

Infectivity and viral load is believed to peak around the time of symptom onset and then decline over the following 3–4 days.<sup>31 32</sup> Considering the median time from symptom presentation to hospitalisation is 4 days and that tracheostomy is not usually considered until at least 7 days after intubation, the risk of infectivity is predicted to be low even if the procedure is performed between the first and second week of ventilation.<sup>33</sup> Our results, therefore, do not support guidance suggesting tracheostomy should be delayed until 14–21 days after intubation to reduce the potential for infection among operators.<sup>12 14</sup> Similarly, our findings and data showing a positive COVID-19 test does not correlate with risk of infectivity later in the disease process, suggest tracheostomy should not be delayed to achieve a negative COVID-19 test. Delaying in these circumstances defers the potential benefits of tracheostomy and increases the risk of complications relating to prolonged endotracheal intubation without any clear benefit to the patient or operators involved in the procedure.

**Collaborators** NJI Hamilton; AGM Schilder; T Jacob; G Ambler; M Singer; MM George; F Green; GM Jama; J Goulder; E Jackson; A Arora; N Kumar; C Schilling; S Laha; I Ahmad; B McGrath; MA Birchall; NS Tolley; G Sandhu; T Tatla; N Sharma; P Stimpson; P Andrews; N Mercer; P Nankivell; O Breik; P Praveen; M Idle; T Martin; S Parmar; P Pracy; C Jennings; J Higginson; K Fan; E Yeung; J Osher; R Bentley; C Huppa; P Stenhouse; K Hussain; S Hodges; F Ryba; P Surda; EK Bhargava; N Amin; J Collins; M Kelly; D Ranford; A Takhar; C Tornari; M Verkerk; C Xie; D Pennell; C Al-Yaghchi; L Ritchie; M Jaafar; M Rouhani; M Ashcroft; N Cereceda-Monteoliva; A Holroyd; J Ng; R Mistry; K Ghufoor; E Warner; H O'Mahony; S Shepherd; N Bhatti; H Drewery; J Hadley; A Mulcahy; H Wilson; R Bhandari; M Griffiths; T Magos; I Balasundaram; M Heliotis; A Loizidou; D York; R Exley; KA Solanki; P Shah; P Kirticumar; A Shah; S Shannon; A Shirazian; Y Bhatt; R Natt; C Spencer;

R D'Souza; N Banga; D Baker; K Dhadwal; Z Abdi; T Exall; I Ekpemi; R Roplekar-Bance; C Walker; N Glibbery; K Karamali; A Li; A Rovira; D Dawson; T Munroe-Gray; P Sethukumar; R Vasanthan; J Phillips; A Williamson; R Saha; M Roberts; H Lee-Six; B Misztal; S Millington; M Musalia; S Suresh; A Cardozo; M Dunbobbins; A Tse; S Shahidi; M Chachlani; K Jolly; J Fussey; M Misurati; M Osborne; S Ashok; H Aboulghait; S Khwaja; R Annolsingh; C Smyth; B Al-Dulaimy; E Omakobia; J Collier; T Browning; A Courtney; P Ward; L Lignos; C Lockie; P Twose; J Heyman; S Berry; P Bishop; D Kathwadia; T Hwara; A Williamson; A Kumar; O Judd; W Parker; TP Davis; T Stubington; T Ali; A Schache; H Koumoullis; E Willcocks; L Skeely; G Dempsey; K Liatsikos ; B Borgatta; J Rodrigues; A Glossop; J Sen; N Lawrence; S Bennett; L Wren; V Politidis; D Dhariwal; S Winter; A Kara; T Hunt; G Tattersall; W Udall; B Hill; S Saha; L Bates; C Smart; D Park; R O'Brien; L Linhartova; P Kirkland; J Staufenberg; K Valchanov; H Buglass; U Sheikh; E Tam; J Williamson; A McGrath; S Siddiq; NW Wahid; H Griffiths; M De; A Amlani; P Deutsch; K Markham; C Hall; S Webster; O Barker; P Sykes; A Gupta; A Easthope; S Glaze; B Morris; D Bondin; D Thorley; K Kapoor; S Sirajuddin; S Fang; F van Damme; O Mattoo; E Paramasivam; E Kershaw; S Dewhurst; S Blakeley; C Chivers; L Lindsey; DJ Lin; A Burns; A Wilson; N Macartney; F Franco; K Goodwin; B Cosway; R Giore; H Cunliffe; M Keil ; S Burrows; D Moulit; D Zolger; J Bakmanidis; D Nair; S Kandiah; M Anwar; A Pericleous; C Hogan; R Temple; D Whitmore; R Sheikh; R Pinto; C Cook; J Broad; U Nagalotimath; E El-Tabal; S Ghaffar; M Dallison; E Leakey; R Harris; J Blair; E France; O Sanders; P Mukherjee; A Gomati; L Moir ; CB Groba; C Davies-Husband; N Seymour; S Mahalingam; D Williams; R Lovett; J Lunn; A Armson; A Balfour; K Steele; K Hilliard; S Ladan; P Paul; P Tsirevelou; V Ratnam; H Turner; N Jain; A Muddaiah; M Celinski; J Smith; J Westwood; J Coakes; R Borg; J McEwan; A Tsagkovits; O Mulla; N Stobbs; G Warner; D Pratap; Z Ghani; J Rocke; S Snape; S Ghosh; A Hassaan; M Cameron; A Daudia; S Menon; S Beckett; R Siau; A Howard ; C Lamont; C Blore; C Pearce; D Zakai; S Biswas; R Moorthy; J Bates; P Gill; E Riley; P Bothma; S Meghji; W Rutherford; A Lloyd; A Syndercombe; P Smith; N Keates; V Srinivasan; M Junaid; M Kumar; T Antonio ; A Vijendren; V Venkatachalam; I Gonzalez; M Lechner; D Chandrasekharan; A Arya; R Brown; H Jones; D Kumar; R Sykes; B Tehan; A Walker; J Whiteside; F Cooper; A Coombs; G Wong; D Walker; S Dennis; A Hormis; A Eldahshan; L Leach; H Paw; M Colombo-Gonzalez; D Chakravarty; S Sanyal; N Mani; B Ranganathan; H Saeed; S Linton; A Thompson; J Whittaker; N Amiruddin; A Sladkowski; R Gohil; AK Abou-Foul; J Ahmed; S Kishwan; G Walton; P Naredia; A Al-Ajami; S Wilkinson; S Okhovat; A Menon; S Mustafa; E Carey; N Vallabh; T Davies; A. Alatsianos; R Townsley.

**Contributors** NH contributed to literature search, figures, study design, data collection, analysis, interpretation and writing. AS contributed to study design, data analysis and interpretation and writing. GA contributed to data analysis, interpretation and writing. TJ and AA contributed to study design, data interpretation and writing. MS contributed to data analysis and interpretation and writing. MG, FG, GJ, JG and EJ contributed to figures, data analysis and editing. All other authors contributed equally under the principles of corporate authorship.

**Funding** The COVIDTrach project is supported by the Wellcome Trust UCL COVID-19 Rapid Response Award and the National Institute for Health Research (NIHR). COVIDTrach is supported by the Wellcome Trust University College London COVID-19 Rapid Response award (BRC732/JK101400) and the NIHR Clinical Research Network. NH is an NIHR Clinical lecturer and is supported by the Royal College of Surgeons (RCSEng) and the Academy of Medical Sciences (SGL021\1046). AGMS is an NIHR senior investigator and director of the NIHR UCLH BRC Hearing Theme; the research of her UCL Ear Institute evidENT team is supported by the NIHR (Biomedical Research Centre, Applied Research Collaboration, Clinical Research Network, Programme Grants for Applied Research, Research for Patient Benefit), Wellcome Trust, RCSEng, and EU Horizon2020. MB is an NIHR senior investigator. Data collection through British Association of Oral Maxillofacial Surgeons was managed by Fabien Puglia and supported by NFORC and Saving faces.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** COVIDTrach has been approved by the UK Research and Ethics Council and the Health Research Authority (20/HRA/3766) as a prospective cohort study, the Scottish Public Benefit and Privacy Panel and Northern Island's Privacy Advisory Committee and was registered as a service evaluation or research study at each participating site.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information. Data are included in the supplementary materials.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- 1 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323:1239-42.
- 2 Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. *JAMA* 2020;323:1545-6.
- 3 Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020;395:1763-70.
- 4 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* 2020;323:1574-81.
- 5 Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. *JAMA Netw Open* 2020;3:e2012270.
- 6 Durbin CG, Perkins MP, Moores LK. Should tracheostomy be performed as early as 72 hours in patients requiring prolonged mechanical ventilation? *Respir Care* 2010;55:76-87.
- 7 Groves DS, Durbin CG. Tracheostomy in the critically ill: indications, timing and techniques. *Curr Opin Crit Care* 2007;13:90-7.
- 8 Jaeger JM, Littlewood KA, Durbin CG. The role of tracheostomy in weaning from mechanical ventilation. *Respir Care* 2002;47:469-80.
- 9 Pierson DJ. Tracheostomy and weaning. *Respir Care* 2005;50:526-33.
- 10 Miles BA, Schiff B, Ganly I, et al. Tracheostomy during SARS-CoV-2 pandemic: recommendations from the new York head and neck Society. *Head Neck* 2020;42:1282-90.
- 11 ENT.UK. COVID-19 tracheostomy guidance. Available: <https://www.entuk.org/covid-19-tracheostomy-guidance-t-jacob-et-al> [Accessed 11 Apr 2020].
- 12 Sommer DD, Engels PT, Weitzel EK, et al. Recommendations from the CSO-HNS Taskforce on performance of tracheostomy during the COVID-19 pandemic. *J Otolaryngol Head Neck Surg* 2020;49:23.
- 13 Association BL. Tracheostomy guideline COVID-19, 2020. Available: <https://www.britishtlaryngological.org/news/tracheostomy-guideline-covid-19> [Accessed 05 May 2020].
- 14 Michetti CP, Bulew CC, Bulger EM, et al. Performing tracheostomy during the Covid-19 pandemic: guidance and recommendations from the critical care and acute care surgery committees of the American association for the surgery of trauma. *Trauma Surg Acute Care Open* 2020;5:e000482.
- 15 Heyd CP, Desiato VM, Nguyen SA, et al. Tracheostomy protocols during COVID-19 pandemic. *Head Neck* 2020;42:1297-302.
- 16 Lavinsky J, Kosugi EM, Baptistella E, et al. An update on COVID-19 for the otorhinolaryngologist - a Brazilian Association of Otolaryngology and Cervicofacial Surgery (ABORL-CCF) Position Statement. *Braz J Otorhinolaryngol* 2020;86:273-80.
- 17 Vukkadala N, Qian ZJ, Holsinger FC, et al. COVID-19 and the otolaryngologist: preliminary evidence-based review. *Laryngoscope* 2020;130:2537-43.
- 18 Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med* 2020;382:1177-9.
- 19 McGrath BA BM, Warrillow SJ, Pandian V, et al. Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. *Lancet Resp Med* 2020.
- 20 COVIDTrach collaborative. COVIDTrach; the outcomes of mechanically ventilated COVID-19 patients undergoing tracheostomy in the UK: interim report. *Br J Surg* 2020;107:e583-e584.
- 21 van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. *Stat Med* 1999;18:681-94.
- 22 Centre ICNARC. ICNARC report on COVID-19 in critical care in Egnland, Wales and Northern Ireland 25 September 2020, 2020. Available: <https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports> [Accessed 28 Sep 2020].
- 23 Young D, Harrison DA, Cuthbertson BH, et al. Effect of early vs late tracheostomy placement on survival in patients receiving mechanical ventilation: the TracMan randomized trial. *JAMA* 2013;309:2121-9.



- 24 Terragni PP, Antonelli M, Fumagalli R, *et al.* Early vs late tracheotomy for prevention of pneumonia in mechanically ventilated adult ICU patients: a randomized controlled trial. *JAMA* 2010;303:1483–9.
- 25 Wang R, Pan C, Wang X, *et al.* The impact of tracheotomy timing in critically ill patients undergoing mechanical ventilation: a meta-analysis of randomized controlled clinical trials with trial sequential analysis. *Heart Lung* 2019;48:46–54.
- 26 Elkbuli A, Narvel RI, Spano PJ, *et al.* Early versus Late Tracheostomy: Is There an Outcome Difference? *Am Surg* 2019;85:370–5.
- 27 Huang H, Li Y, Ariani F, *et al.* Timing of tracheostomy in critically ill patients: a meta-analysis. *PLoS One* 2014;9:e92981.
- 28 Meng L, Wang C, Li J, *et al.* Early vs late tracheostomy in critically ill patients: a systematic review and meta-analysis. *Clin Respir J* 2016;10:684–92.
- 29 Riestra-Ayora J, Yanes-Diaz J, Penuelas O, *et al.* Safety and prognosis in percutaneous vs surgical tracheostomy in 27 patients with COVID-19. *Otolaryngol Head Neck Surg* 2020;163:462–4.
- 30 Williamson A, Roberts MT, Phillips J, *et al.* Early percutaneous tracheostomy for patients with COVID-19. *Anaesthesia* 2021;76:138–9.
- 31 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;581:465–9.
- 32 McGrath BA, Brenner MJ, Warrillow SJ, *et al.* Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. *Lancet Respir Med* 2020;8:717–25.
- 33 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62.
- 34 Harris PA, Taylor R, Minor BL, *et al.* The REDCap Consortium: building an international community of software platform partners. *J Biomed Inform* 2019;95:103208.
- 35 Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377–81.



Variable	% answered	Total number expected	Total number completed	Number missing
Age	100	1605	1605	0
Gender	100	1605	1604	1
COVID status	100	1605	1599	6
Method of tracheostomy	100	1605	1598	7
Mortality	100	1605	1601	4
Wean from ventilator	100	1326	1320	6
CRP before tracheostomy	99	1605	1583	22
Location of tracheostomy	99	1605	1594	11
Surgical specialty performing operation	99	1605	1588	17
Intraoperative complications	99	1605	1581	24
Discharge from hospital within 28 days	99	1326	1315	11
Intubation to tracheostomy (days)	98	1605	1565	40
Inotropic support	98	1605	1565	40
Indication for tracheostomy	98	1605	1569	36
Neck factors affecting tracheostomy	98	1605	1567	38
Use of PPE - mask use	98	1605	1578	27
FiO2 on day of tracheostomy	97	1605	1549	56
Cause of death	97	299	291	8
COVID-19 amongst operators	97	1605	1558	47
PEEP on day of tracheostomy	96	1605	1533	72
Guidance method for perc tracheostomy	96	771	736	35
Co-morbidities	95	1605	1521	84
Admission to intubation (days)	95	1605	1518	87
Use of NIV	95	1605	1525	80
Postoperative complications before wean	95	1605	1530	75
Total length of critical care in non-survivors	95	279	264	15
Type of tracheostomy tube	94	1605	1509	96
Temperature before tracheostomy	92	1605	1481	124
P02 on day of tracheostomy	92	1605	1480	125
Outcome of last test	91	1605	1455	150
BMI	90	1605	1437	168
Number of tests	90	1605	1441	164
Time from test to tracheostomy (days)	90	1605	1451	154
Tracheostomy decannulation	90	1326	1195	131
Time from tracheostomy to wean	88	1326	1164	162
Postoperative complications after wean	86	1326	1142	184
Total length of critical care in survivors	85	1326	1121	205

**Supplementary Table 1.** Data completeness for each variable examined with total number of missing answers.

	Survived (n=1319)	Died (n=286)
Age		
<30	22 (88.0%)	3 (12.0%)
30-49	293 (89.6%)	34 (10.4%)
50-69	854 (82.9%)	176 (17.1%)
70+	150 (67.3%)	73 (32.7%)
Sex		
Male	909 (81.0%)	213 (19.0%)
Female	409 (84.9%)	73 (15.1%)
Missing	1	0
Body Mass Index		
<18.5	12 (92.3%)	1 (7.7%)
18.5-25	286 (80.6%)	69 (19.4%)
25-30	395 (82.6%)	83 (17.4%)
30-40	391 (83.5%)	77 (16.5%)
40+	109 (89.3%)	13 (10.7%)
Missing	126	43
Number of Comorbidities		
None	390 (82.3%)	84 (17.7%)
One	458 (81.3%)	105 (18.7%)
Two or more	471 (82.9%)	97 (17.1%)
CRP	112.0 (84.6)	151.4 (98.4)
Missing	19	3
Downward CRP		
No	388 (77.4%)	113 (22.6%)
Yes	904 (84.5%)	166 (15.5%)
Missing	27	7
Anticoagulant		
No	700 (84.7%)	126 (15.3%)
Yes	546 (78.2%)	152 (21.8%)
Missing	73	8
Inotropic support		
No	833 (86.9%)	126 (13.1%)
Yes	456 (75.2%)	150 (24.8%)
Missing	30	10
Use of NIV		
No	721 (82.5%)	153 (17.5%)
Yes	535 (82.2%)	116 (17.8%)
Missing	63	17
Days of ventilation before tracheostomy		
<= 7	99 (63.1%)	58 (36.9%)
8 to 12	293 (80.1%)	73 (19.9%)
> 12	895 (86.0%)	146 (14.0%)
Missing	32	9
FiO2 requirement	38.5 (11.1)	46.7 (13.7)
Missing	47	9
PO2 requirement	10.9 (7.1)	11.2 (10.6)
Missing	112	13
PEEP setting	7.9 (2.4)	8.9 (2.1)
Missing	59	13
Method of tracheostomy		
Open	681 (85.6%)	115 (14.4%)
Percutaneous	614 (79.6%)	157 (20.4%)
Missing / Hybrid	24	14

**Supplementary Table 2.** Baseline and demographic characteristics by mortality. Values are either N (%) or mean (SD)

Varibale	N	Days (n=1165)	P
Age			<0.001
<30	18	8.5 (7 to 12)	
30-49	260	10 (6 to 15)	
50-69	753	12 (7 to 18)	
70+	134	13 (8 to 23)	
Sex			<0.001
Male	798	12 (7 to 19)	
Female	366	9.5 (6 to 16)	
Missing	1		
Body Mass Index			0.023
<18.5	12	11 (6 to 22)	
18.5-25	260	13 (7 to 22)	
25-30	356	11 (7 to 17.5)	
30-40	349	11 (7 to 17)	
40+	97	10 (7 to 15)	
Missing	91		
Number of Comorbidities			0.521
None	351	11 (6 to 18)	
One	394	12 (7 to 18)	
Two or more	420	11 (7 to 17)	
CRP	1152	0.11	<0.001
Missing	13		
Downward CRP			0.574
No	338	12 (7 to 19)	
Yes	807	11 (7 to 18)	
Missing	20		
Anticoagulant			<0.001
No	628	10 (6 to 16)	
Yes	492	12 (8 to 21)	
Missing	45		
Inotropic support			0.002
No	757	11 (6 to 18)	
Yes	389	12 (8 to 19)	
Missing	19		
Use of NIV			<0.001
No	644	10 (6 to 17)	
Yes	486	12 (8 to 20)	
Missing	35		
Days of ventilation before tracheostomy			0.107
<= 7	83	12 (7 to 17)	
08-Dec	265	11 (7 to 18)	
> 12	810	11 (7 to 18)	
Missing	7		
FiO2 requirement	1145	0.21	<0.001
Missing	20		
PO2 requirement	1096	-0.07	0.022
Missing	69		
PEEP setting	1136	0.17	<0.001
Missing	29		
Method of tracheostomy			0.096
Open	586	11 (6 to 18)	
Percutaneous	557	12 (7 to 18)	
Missing / Hybrid	22		

**Supplementary Table 3.** Days to Wean Success. Values are Spearman correlation coefficient or median (inter-quartile range). P-values are from either spearman correlation or Kruskal-Wallis test.